Although the precise biological role and mechanisms underlying its contribution to immune evasion are the subjects of ongoing investigation, CD276’s pronounced expression in cancerous tissues and vasculature, including its prevalence in as many as 98% of renal cell carcinoma (RCC) blood vessels (26), underscores its potential as a distinctive and potent vessel-specific marker of cancer. Here, CD276 is linked to renal cell carcinoma.